TY - JOUR
T1 - Acute COVID-19 Infection in a Pediatric Patient with ROHHAD
AU - Udrea, Daniel S.
AU - Lopez, Merrick
AU - Avesar, Michael
AU - Qureshi, Sonea
AU - Moretti, Anthony
AU - Abd-Allah, Shamel A.
AU - Chandnani, Harsha K.
AU - Lopez, Merrick R.
N1 - Thieme. All rights reserved.
PY - 2020/10/26
Y1 - 2020/10/26
N2 - The novel coronavirus (severe acute respiratory syndrome coronavirus-2) has led to a global pandemic. In the adult population, coronavirus disease 2019 (COVID-19) has been found to cause multiorgan system damage with predicted long-term sequelae. We present a case of a 10-year-old boy with a history of ROHHAD (rapid-onset obesity with hypothalamic dysregulation, hypoventilation, and autonomic dysregulation) who presented with hypoxia, emesis, and abdominal pain. Imaging found bilateral ground glass opacities in the lungs and a pericardial effusion. Laboratory evaluation was concerning for elevated inflammatory markers. Remdesivir, hydroxychloroquine, and anticoagulation (heparin and enoxaparin) were utilized. The patient's severe respiratory failure was managed with conventional mechanical ventilation, inhaled nitric oxide, and airway pressure release ventilation. We hope that this report provides insight into the course and management of the severe acute pediatric COVID-19 patient, specifically with underlying comorbidities such as ROHHAD. Clinical trial registration is none.
AB - The novel coronavirus (severe acute respiratory syndrome coronavirus-2) has led to a global pandemic. In the adult population, coronavirus disease 2019 (COVID-19) has been found to cause multiorgan system damage with predicted long-term sequelae. We present a case of a 10-year-old boy with a history of ROHHAD (rapid-onset obesity with hypothalamic dysregulation, hypoventilation, and autonomic dysregulation) who presented with hypoxia, emesis, and abdominal pain. Imaging found bilateral ground glass opacities in the lungs and a pericardial effusion. Laboratory evaluation was concerning for elevated inflammatory markers. Remdesivir, hydroxychloroquine, and anticoagulation (heparin and enoxaparin) were utilized. The patient's severe respiratory failure was managed with conventional mechanical ventilation, inhaled nitric oxide, and airway pressure release ventilation. We hope that this report provides insight into the course and management of the severe acute pediatric COVID-19 patient, specifically with underlying comorbidities such as ROHHAD. Clinical trial registration is none.
UR - http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1718874.pdf
UR - https://www.mendeley.com/catalogue/238b0549-2d66-3c9c-95c7-5977b79e903d/
U2 - 10.1055/S-0040-1718874
DO - 10.1055/S-0040-1718874
M3 - Article
C2 - 36267858
VL - 11
SP - 309
EP - 312
JO - Journal of pediatric genetics
JF - Journal of pediatric genetics
IS - 4
ER -